Ally Bridge Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Ally Bridge Group’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.67M	Buy	+80,859	New	+$5.65M	4.58%	7
2025 Q4	–	Sell	-70,778	Closed	-$4.21M	–	30
2025 Q3	$4.21M	Sell	70,778 -50,404	-42%	-$2.48M	2.56%	17
2025 Q2	$4.91M	Sell	121,182 -6,750	-5%	-$304K	4.08%	9
2025 Q1	$6.57M	Sell	127,932 -45,212	-26%	-$2.23M	5.92%	5
2024 Q4	$9.59M	Sell	173,144 -148,754	-46%	-$6.76M	8.22%	2
2024 Q3	$10.6M	Buy	+321,898	New	+$9.05M	5.67%	2

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ally Bridge Group's TARS Position: Q1 2026 in Review

Ally Bridge Group opened a new position in Tarsus Pharmaceuticals (TARS) in Q1 2026: 80,859 shares worth $5.67M. The stake represents 4.58% of the portfolio and ranks #7 among its holdings. This is a return to the name: Ally Bridge Group previously reported a position in TARS as recently as Q3 2025.

Ally Bridge Group first reported a position in TARS in Q3 2024 and has held it in 6 quarters since. The position peaked at $10.6M in Q3 2024. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Ally Bridge Group held 80,859 shares of Tarsus Pharmaceuticals worth $5.67M as of Q1 2026.
Tarsus Pharmaceuticals was a new Ally Bridge Group position in Q1 2026.
Tarsus Pharmaceuticals made up 4.58% of Ally Bridge Group's portfolio in Q1 2026, its #7 holding.
Ally Bridge Group first reported a position in Tarsus Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
Ally Bridge Group's Tarsus Pharmaceuticals position peaked at $10.6M in Q3 2024.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.